MyFinsight
Home
About
Contact
Download
Download image
Rest Of World
$140,187K
Latin America
$97,618K
Europe
$195,184K
US
$274,114K
Net income (loss)
-$30,744K
(-128.98%↓ Y/Y)
ALDURAZYME-Sales Channel Through
Intermediary
$53,709K
Products Excluding
ALDURAZYME-Sales Channel...
$707,103K
Provision for income taxes
$4,420K
(-84.42%↓ Y/Y)
Income (loss) before
income taxes
-$26,324K
(-119.58%↓ Y/Y)
Other income, net
$5,093K
(-6.77%↓ Y/Y)
Interest income
$17,854K
(-1.10%↓ Y/Y)
Royalty And Other
$15,321K
Product
$760,812K
Interest expense
$2,579K
(-13.11%↓ Y/Y)
Income (loss) from
operations
-$46,692K
(-141.00%↓ Y/Y)
Total revenues
$776,133K
(4.08%↑ Y/Y)
Total operating
expenses
$822,825K
(30.23%↑ Y/Y)
Intangible asset
amortization
$4,847K
(-3.23%↓ Y/Y)
Selling, general and
administrative
$268,415K
(5.89%↑ Y/Y)
Research and development
$409,478K
(121.46%↑ Y/Y)
Cost of sales
$140,085K
(-25.67%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
bmrn: the income statement
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)
biomarin-logo-svg
BIOMARIN PHARMACEUTICAL INC (BMRN)